HRP20160125T1 - Spojevi 1h-indazol-3-karboksamida kao inhibitori glikogen sinteze kinaze-3 beta - Google Patents
Spojevi 1h-indazol-3-karboksamida kao inhibitori glikogen sinteze kinaze-3 beta Download PDFInfo
- Publication number
- HRP20160125T1 HRP20160125T1 HRP20160125TT HRP20160125T HRP20160125T1 HR P20160125 T1 HRP20160125 T1 HR P20160125T1 HR P20160125T T HRP20160125T T HR P20160125TT HR P20160125 T HRP20160125 T HR P20160125T HR P20160125 T1 HRP20160125 T1 HR P20160125T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- indazole
- alkoxy
- carboxamide
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12156292 | 2012-02-21 | ||
| PCT/EP2013/052400 WO2013124158A1 (en) | 2012-02-21 | 2013-02-07 | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| EP13704910.2A EP2817302B1 (en) | 2012-02-21 | 2013-02-07 | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160125T1 true HRP20160125T1 (hr) | 2016-03-11 |
Family
ID=47739223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160125TT HRP20160125T1 (hr) | 2012-02-21 | 2013-02-07 | Spojevi 1h-indazol-3-karboksamida kao inhibitori glikogen sinteze kinaze-3 beta |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9611249B2 (enExample) |
| EP (1) | EP2817302B1 (enExample) |
| JP (1) | JP6141331B2 (enExample) |
| KR (1) | KR20140130124A (enExample) |
| CN (1) | CN104093712B (enExample) |
| AR (1) | AR090086A1 (enExample) |
| AU (1) | AU2013224302B2 (enExample) |
| BR (1) | BR112014018655B1 (enExample) |
| CA (1) | CA2860250C (enExample) |
| CY (1) | CY1117469T1 (enExample) |
| DK (1) | DK2817302T3 (enExample) |
| EA (1) | EA024939B1 (enExample) |
| ES (1) | ES2564961T3 (enExample) |
| GE (1) | GEP20166489B (enExample) |
| HR (1) | HRP20160125T1 (enExample) |
| HU (1) | HUE026893T2 (enExample) |
| IL (1) | IL233824A (enExample) |
| ME (1) | ME02353B (enExample) |
| MX (1) | MX351287B (enExample) |
| PL (1) | PL2817302T3 (enExample) |
| RS (1) | RS54567B1 (enExample) |
| SG (2) | SG11201403602WA (enExample) |
| SI (1) | SI2817302T1 (enExample) |
| SM (1) | SMT201600053B (enExample) |
| UA (1) | UA112564C2 (enExample) |
| WO (1) | WO2013124158A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2860466C (en) * | 2012-02-21 | 2020-02-18 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.S.P.A. | Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2942687A1 (en) | 2014-03-20 | 2015-09-24 | Samumed, Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
| AU2017272505B9 (en) | 2016-06-01 | 2021-10-28 | Bayer Pharma Aktiengesellschaft | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals |
| CN109563071B (zh) * | 2016-06-08 | 2021-08-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4途径抑制剂的化学化合物 |
| SG11202008029UA (en) * | 2018-02-23 | 2020-09-29 | Samumed Llc | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
| IL278330B2 (en) | 2018-05-07 | 2024-06-01 | Acraf | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| IL279155B2 (en) | 2018-06-05 | 2025-02-01 | Actuate Therapeutics Inc | Methods for treating malignant lymphoid tissue proliferation disorders |
| US12084426B2 (en) | 2018-09-13 | 2024-09-10 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| EA202190718A1 (ru) | 2018-09-13 | 2021-07-01 | Бристол-Маерс Сквибб Компани | Индазолкарбоксамиды в качестве ингибиторов киназ |
| US20240051939A1 (en) * | 2020-12-08 | 2024-02-15 | Disarm Therapeutics, Inc. | Benzopyrazole inhibitors of sarm1 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705498A (en) | 1992-11-05 | 1998-01-06 | Smithkline Beecham Plc. | Piperidine derivatives as 5-HT4 receptor antagonists |
| IT1291569B1 (it) * | 1997-04-15 | 1999-01-11 | Angelini Ricerche Spa | Indazolammidi come agenti serotoninergici |
| GB0218625D0 (en) * | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| EP1546156A1 (en) * | 2002-08-10 | 2005-06-29 | Astex Technology Limited | 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors |
| ITMI20030287A1 (it) | 2003-02-18 | 2004-08-19 | Acraf | Indazolammidi dotate di attivita' analgesica metodo, per |
| ITMI20030972A1 (it) | 2003-05-15 | 2004-11-16 | Acraf | Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende. |
| WO2005014554A1 (en) * | 2003-08-08 | 2005-02-17 | Astex Therapeutics Limited | 1h-indazole-3-carboxamide compounds as mapkap kinase modulators |
| GB0414438D0 (en) * | 2004-06-28 | 2004-07-28 | Syngenta Participations Ag | Chemical compounds |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| EP1692939A1 (en) * | 2005-02-19 | 2006-08-23 | Bayer CropScience S.A. | Pesticidal substituted piperidines |
| WO2008154241A1 (en) * | 2007-06-08 | 2008-12-18 | Abbott Laboratories | 5-heteroaryl substituted indazoles as kinase inhibitors |
| UA99927C2 (uk) | 2007-11-12 | 2012-10-25 | Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А. | Медикамент, який є активним при невропатичному болі |
| US8377968B2 (en) * | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
| TW201040191A (en) | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US7947728B1 (en) * | 2009-11-11 | 2011-05-24 | Hoffmann-La Roche Inc. | Indole and indazole analogs as glycogen synthase activators |
-
2013
- 2013-02-07 MX MX2014009297A patent/MX351287B/es active IP Right Grant
- 2013-02-07 EP EP13704910.2A patent/EP2817302B1/en active Active
- 2013-02-07 ME MEP-2016-29A patent/ME02353B/me unknown
- 2013-02-07 BR BR112014018655-3A patent/BR112014018655B1/pt active IP Right Grant
- 2013-02-07 PL PL13704910T patent/PL2817302T3/pl unknown
- 2013-02-07 SG SG11201403602WA patent/SG11201403602WA/en unknown
- 2013-02-07 CA CA2860250A patent/CA2860250C/en active Active
- 2013-02-07 EA EA201491449A patent/EA024939B1/ru unknown
- 2013-02-07 DK DK13704910.2T patent/DK2817302T3/en active
- 2013-02-07 SG SG10201701649YA patent/SG10201701649YA/en unknown
- 2013-02-07 JP JP2014556989A patent/JP6141331B2/ja active Active
- 2013-02-07 KR KR20147022708A patent/KR20140130124A/ko not_active Ceased
- 2013-02-07 SI SI201330134T patent/SI2817302T1/sl unknown
- 2013-02-07 GE GEAP201313563A patent/GEP20166489B/en unknown
- 2013-02-07 CN CN201380007411.7A patent/CN104093712B/zh active Active
- 2013-02-07 WO PCT/EP2013/052400 patent/WO2013124158A1/en not_active Ceased
- 2013-02-07 HU HUE13704910A patent/HUE026893T2/en unknown
- 2013-02-07 US US14/373,100 patent/US9611249B2/en active Active
- 2013-02-07 HR HRP20160125TT patent/HRP20160125T1/hr unknown
- 2013-02-07 AU AU2013224302A patent/AU2013224302B2/en active Active
- 2013-02-07 ES ES13704910.2T patent/ES2564961T3/es active Active
- 2013-02-07 RS RS20160132A patent/RS54567B1/sr unknown
- 2013-02-19 AR ARP130100502A patent/AR090086A1/es active IP Right Grant
- 2013-07-02 UA UAA201406961A patent/UA112564C2/uk unknown
-
2014
- 2014-07-27 IL IL233824A patent/IL233824A/en active IP Right Grant
-
2016
- 2016-02-23 SM SM201600053T patent/SMT201600053B/xx unknown
- 2016-03-15 CY CY20161100219T patent/CY1117469T1/el unknown
-
2017
- 2017-02-22 US US15/439,172 patent/US10160746B2/en active Active
- 2017-03-07 US US15/451,966 patent/US20170174657A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160125T1 (hr) | Spojevi 1h-indazol-3-karboksamida kao inhibitori glikogen sinteze kinaze-3 beta | |
| HRP20160124T1 (hr) | Uporaba spojeva 1h-indazol-3-karboksamida kao inhibitora glikogen sinteze kinaze-3 beta | |
| JP2015506993A5 (enExample) | ||
| TR201904614T4 (en) | Novel pyrazole derivative. | |
| EP2968335A4 (en) | SYNTHESIS AND COMPOSITION OF COMPOUNDS USED TO TARGET TUMOR FORMING OF CONJUGATED AMINO ACID COMPOUNDS | |
| PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| MX2017015734A (es) | Profarmacos que comprenden un conjugado de acido hialuronico enlazador agonista dual de glp-1/glucagon. | |
| SI2935307T1 (en) | Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures | |
| SI3125888T1 (en) | 2,4-TIAZOLIDINDION DERIVATIVES FOR TREATMENT OF CENTRAL STYLE SYSTEM DISEASE | |
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| BR112015020998A2 (pt) | compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| BR112014027359A2 (pt) | moduladores da série de reação complementar e usos dos mesmos | |
| BR112012023178A2 (pt) | ramidinas substituídas como antagonistas de receptor prostaglandina 2 | |
| PE20150968A1 (es) | Nuevos acidos indaniloxi dihidrobenzofuranil aceticos | |
| BR112013016770A2 (pt) | formulação farmacêutica, fármaco biofarmacêutico, seringa ou caneta pré-preenchida, uso de uma formulação farmacêutica | |
| RU2020123899A (ru) | Новые соединения, ингибирующие mtor | |
| BR112017016378A2 (pt) | composições da pró-droga de fumarato de monometila | |
| ME02833B (me) | Prekursor leka aminokiseline koja sadrži fluor | |
| PH12016500427A1 (en) | Ethynyl derivatives | |
| JP2015502371A5 (enExample) | ||
| WO2014068463A3 (en) | Compositions and methods for the treatment of inflammation and metabolic disorders | |
| ME02351B (me) | Derivati 2 -oxo- 1-imidazolidinil imidazotiadiazol | |
| RU2016151411A (ru) | Производные о-алкил-бензилиденгуанидина и их терапевтическое использование для лечения заболеваний, связанных с накоплением неправильно свернутых белков | |
| HRP20220664T1 (hr) | 1h-indazol-3-karboksamid spojevi kao inhibitori glikogen sintaza kinaze 3 beta | |
| UY38027A (es) | Moduladores de molécula pequeña del dominio btb de keap1 |